Aarti Drugs has announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company achieved its highest-ever quarterly revenue from operations of ₹826 crore and its highest-ever quarterly EBITDA of ₹138 crore. This performance reflects strong volume growth and realisations across its API, formulations, and Specialty Chemicals portfolio, with significant year-over-year growth in revenue and EBITDA.
Aarti Drugs Achieves Record Financial Performance in Q2 FY27
Aarti Drugs Limited (NSE: AARTIDRUGS; BSE:524348) has announced its unaudited financial results for the quarter and half-year ended September 30, 2026, marking a landmark period for the company. The company reported its highest-ever quarterly revenue from operations, reaching ₹826 crore, and achieved its highest-ever quarterly EBITDA of ₹138 crore. This robust performance signifies substantial growth and operational efficiency.
Key Financial Highlights – Q2 FY27
In the second quarter of fiscal year 2027 (Q2 FY27), Aarti Drugs saw its revenue stand at ₹828.8 crore, representing a significant 27% year-over-year (YoY) growth compared to ₹652.9 crore in Q2 FY26. The company’s EBITDA recorded an impressive 63% YoY growth, escalating to ₹137.9 crore from ₹84.4 crore in the prior-year period. The EBITDA margin expanded by 370 basis points to 16.6%, its highest level in nearly six years. Profit After Tax (PAT) also saw a substantial increase of 83% YoY, reaching ₹82.8 crore, with the PAT margin expanding by 310 bps to 10.0%.
H1 FY27 Performance Shows Strong Momentum
For the first half of fiscal year 2027 (H1 FY27), Aarti Drugs reported a consolidated revenue of ₹1,532.4 crore, a 23% increase compared to ₹1,243.7 crore in H1 FY26. EBITDA for H1 FY27 grew by 48% YoY to ₹234.8 crore, with the EBITDA margin improving by 250 bps to 15.3%. PAT for the first half of the fiscal year was ₹132.9 crore, a 34% growth YoY, and the PAT margin stood at 8.7%.
Segmental Performance Update
The company’s performance was driven by broad-based growth across its business segments. The API segment registered a revenue of ₹604.5 crore in Q2 FY27, a 17% YoY increase. The Formulation segment experienced a remarkable 58% YoY growth, with revenue standing at ₹130.0 crore. The Specialty Chemicals segment nearly doubled its revenue, showing a 92% YoY growth to ₹71.8 crore, largely due to the scaling up of its Sayakha facility.
Leadership Transition and Future Outlook
The announcement also coincided with a significant leadership transition. Mr. Prakash M. Patil retired as Chairman, Managing Director, and CEO after a dedicated service. Mr. Rashesh Gogri has taken over as Chairman, and Mr. Adhish Patil assumes the role of Managing Director. The company aims to build itself into a more integrated, diversified, and globally relevant pharmaceutical entity, focusing on improving capacity utilization, expanding its regulatory footprint, and creating sustainable growth.
Source: BSE
